Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 1 (1), 195-217

Efficacy and Safety of the Immunization With DNA for Alzheimer's Disease in Animal Models: A Systematic Review From Literature


Efficacy and Safety of the Immunization With DNA for Alzheimer's Disease in Animal Models: A Systematic Review From Literature

Yandara Akamine Martins et al. J Alzheimers Dis Rep.


Background: Alzheimer's disease (AD) is a neurodegenerative disease that does not have a proven cure; however, one of the most promising strategies for its treatment has been DNA vaccines.

Objective: The present review is aimed to report the new developments of the efficacy and safety of DNA vaccines for AD in animal models.

Method: The method PRISMA was used for this review. The article search was made in the electronic databases PubMed, LILACS, and Scopus using the descriptors ''Alzheimer disease" and ''Vaccine, DNA". Articles published between January 2001 and September 2017 in English, Portuguese, and Spanish were included.

Results: Upon the consensus, the researchers identified 28 original articles. The studies showed satisfying results as for the decrease of amyloid plaques in mouse, rabbits, and monkeys brains using mostly the DNA Aβ42 vaccine, AV-1955, and AdPEDI-(Aβ1-6)11, mainly with a gene gun. In addition to a reduction in tau by the first DNA vaccine (AV-1980D) targeting this protein. The use of adjuvants and boosters also had positive results as they increased the destruction of the amyloid plaques and induced an anti-inflammatory response profile without side effects.

Conclusion: The results of DNA vaccines targeting the amyloid-β and the tau protein with or without adjuvants and boosters were promising in reducing amyloid plaques and tau protein without side effects in animals. Although there are many vaccines being tested in animals, few reach clinical trials. Thus, as a future perspective, we suggest that clinical studies should be conducted with vaccines that have been promising in animal models (e.g., DNA Aβ42 vaccine, AV-1955, and AdPEDI-(Aβ1-6)11).

Keywords: Alzheimer’s disease; DNA vaccine; animal models; immunization; mouse; side effects; therapeutic efficacy.


PRISMA flowchart with selection criteria of included articles in the systematic review of DNA immunotherapy in Alzheimer’s disease in animal models.

Similar articles

See all similar articles

Cited by 1 article


    1. Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology 76, 27–50. - PubMed
    1. Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778–1783. - PMC - PubMed
    1. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, Noda M, Fukunari A, Muramatsu S, Itokazu Y, Sato K, Takahashi H, Teplow DB, Nabeshima Y, Kakita A, Imahori K, Hoshi M (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains. J Biol Chem 284, 32895–32905. - PMC - PubMed
    1. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12, 383–388. - PubMed
    1. Kumar A, Dogra S (2008) Neuropathology and therapeutic management of Alzheimer’s disease - An update. Drugs Future 33, 433.

LinkOut - more resources